Full Breakdown
Lenacapavir: A Breakthrough in HIV Prevention for Transgender Individuals
12/17/2025, 10:53:33 AM
Overview of Lenacapavir's Impact on Hormone Therapy
A recent study has confirmed that lenacapavir, the longest-acting injectable form of pre-exposure prophylaxis (PrEP) for HIV prevention, does not adversely affect hormone therapy for transgender individuals. Marketed as Yeztugo by Gilead Sciences, lenacapavir was approved by the FDA in June 2025, offering a significant advancement in long-lasting protection against HIV, which disproportionately affects the transgender community.
Study Details and Findings
The research, led by Dr. Jill Blumenthal from the University of California San Diego, focused on the interactions between lenacapavir and gender-affirming hormones, including testosterone and estradiol. The study involved a pharmacokinetic analysis of blood samples from over 2,000 participants, of whom 14% identified as trans women, 1% as trans men, and 6% as nonbinary. Among these, 253 participants reported using gender-affirming hormones. The results indicated that hormone levels remained stable before and after the administration of lenacapavir, demonstrating no clinically significant impact on hormone therapy concentrations.
Importance of the Findings
The findings address a critical barrier to PrEP uptake among transgender individuals, who have historically been hesitant to use antiretrovirals due to concerns about their effects on hormone therapy. Prior studies indicated that only 20% of gender-diverse individuals have utilized PrEP, with adherence rates as low as 30%. In contrast, 45% of gay and bisexual men at high risk for HIV in the U.S. have used PrEP as of 2023. The introduction of lenacapavir, which requires administration only twice a year and is estimated to cost under $60 annually, could significantly improve these low usage rates.
Official Statements & Responses
Researchers emphasized that the data support the concurrent use of lenacapavir PrEP and gender-affirming hormone therapy without the need for dose adjustments. They noted, “Taken together with our prior findings that gender-affirming hormone therapy had no significant effect on lenacapavir pharmacokinetics, these data support the concurrent use of twice-yearly lenacapavir PrEP and feminizing or masculinizing gender-affirming hormone therapy.”
Criticism & Opposition
Despite the positive findings, some critics remain cautious about the broader implications of introducing new medications. Concerns about accessibility, affordability, and the need for comprehensive education on PrEP among healthcare providers and the transgender community persist.
Conclusion
The study's results represent a significant step forward in HIV prevention strategies for transgender individuals, potentially increasing PrEP uptake and adherence in a population that is disproportionately affected by HIV. The approval of lenacapavir may pave the way for improved health outcomes and greater access to essential preventive care for gender-diverse individuals.
